Anyone heard of any new Fat burning Drugs out or on the horizon?

[Fitness2829]

Has anyone heard of anything new coming out for fat burning?? I had heard of some new drug called Accomplia? I think its just an appetite suppresent though? Anyone know of anything or have any info?

 

[terryd5150]

Nope.

 

[TooPowerful4u]

Nope.

LMFAO what a response

 

[G.E.R.M]

..

i know they will release a study soon regarding fat buring.

its gonna say work harder and lose more fat.

or just eat some DNP

 

[AWN2004]

Or.....

Go on the "All Big Mac diet as a tribute to Dave Palumbo...right buddy."

 

[dragonfire101]

Why dont you just type it into a yahoo search. This was the first hit I got. Some overseas pharms appear to be selling it also although its not approved yet by FDA.

Two Pivotal Studies Indicate Acomplia(TM)(Rimonabant) Offers a Novel Approach to Cardiovascular Risk Management In Overweight/Obese People and Smokers

RIO-LIPIDS AND STRATUS-US Study Results Announced Today At American College of Cardiology Annual Meeting

NEW ORLEANS, March 9 /PRNewswire-FirstCall/ -- Early results of two Phase III studies with ACOMPLIA(TM) (rimonabant), the first in a new class of therapeutics called Selective CB1 Blockers, indicate that overweight/obese patients with untreated dyslipidemia (high triglycerides and/or high total cholesterol/HDL cholesterol ratio) lost weight in one year while improving their lipid and glucose profiles, and that smokers who had previously unsuccessfully tried to quit smoking, were able to quit in 10 weeks without post cessation weight gain. The results of both the RIO-Lipids (Rimonabant In Obesity) and STRATUS-US (STudies with Rimonabant And Tobacco USe) trials were presented for the first time to the scientific community at the American College of Cardiology annual meeting in New Orleans, LA.

"Obesity and smoking are dangerous diseases that are reaching epidemic proportions around the world and are well known risk factors for cardiovascular diseases," said Chris Cannon M.D., Associate Professor of Medicine at Harvard Medical School and Associate Physician in the Cardiovascular Division of Brigham and Women's Hospital, Boston. "In addition, they frequently cluster with other metabolic risk factors such as dyslipidemia and diabetes. These results appear to show that rimonabant could become an important agent in the management of cardiovascular risk in these patient populations."

What these risk factors have in common is that they all seem to be related to an over-stimulated Endocannabinoid System (EC System), a natural physiological system believed to play a role in maintaining energy balance through the regulation of food intake and energy expenditure. The EC system is also believed to play a role in tobacco dependence. In overweight/obese people, excessive eating and fat accumulation is associated with over- activation of the EC System, which also becomes unbalanced with chronic tobacco use. This leads to a series of signals transmitted by a receptor found in the EC System, the CB1 receptor, which can be found in the brain and in other parts of the body (i.e. adipose tissue or "fat cells" which are involved in lipid and glucose metabolism). ACOMPLIA(TM) works by selectively blocking CB1 receptors, helping to normalize the disrupted EC System. In overweight/obese people, this is thought to result in weight loss, reduced waist circumference and improvement of lipid and glucose metabolism. In those that smoke, ACOMPLIA(TM) thought to help people to stop smoking without significant post-cessation weight gain.

RIO-Lipids Study Findings

RIO-Lipids, an international multi-center, double-blind, placebo- controlled study, enrolled 1,036 overweight or obese patients with dyslipidemia (high triglycerides and/or high total cholesterol/HDL cholesterol ratio) and a Body Mass Index (BMI) between 27 and 40 kg/m2. Patients were

randomized to receive either a daily, fixed dose of ACOMPLIA(TM) 5 mg or 20 mg or placebo along with a reduced calorie diet for one year.

Patients treated for one year with rimonabant 20 mg per day lost 8.6 kg (almost 20 lbs) vs. a loss of only 2.3 kg (5 lbs) on placebo (p<0.001). Nearly 75% (p<0.001 vs. placebo) of patients treated for one year with ACOMPLIA(TM) 20 mg lost over 5% of their body weight as compared to 41.8% (p = 0.002 vs. placebo) of patients on ACOMPLIA(TM) 5 mg and 27.6% of patients in the placebo group. Moreover, 44.3% (p<0.001 vs. placebo) lost more than 10% of their body weight when treated for one year with ACOMPLIA(TM) 20 mg vs. 16.3% of patients on ACOMPLIA(TM) 5 mg or 10.3% of patients on placebo. In addition to weight loss, RIO-Lipids was designed to assess a number of associated important cardiovascular risk factors. All improvements in risk factors were statistically significant vs. the control group. In fact, the number of patients diagnosed as having metabolic syndrome1 at baseline (52.9%) was reduced by half (25.8%) after treatment with ACOMPLIA(TM) 20 mg (p<0.0001 compared to placebo). Study findings for rimonabant 20 mg include:


-- Waist circumference reduction of 9.1 cm (3.5 inches) in patients
treated for a year (completers) with rimonabant 20 mg
(p<0.001 vs. placebo).

-- Average increase of 23% in HDL-cholesterol in completers
(p<0.001 vs. placebo).

-- Average reduction of 15% in triglycerides in completers
(p<0.001 vs. placebo).

-- A positive shift in LDL particle size, with a reduction
(p=0.002 vs. placebo) in the proportion of smaller dense atherogenic
LDL particles, which are associated with cardiovascular risk, and an
increase (p<0.001 vs. placebo) in the proportion of larger, less
atherogenic LDL particles.

-- In a sub-group of patients adiponectin and leptin levels were
measured. After one year of treatment, a significant increase of
adiponectin level from baseline was found in the rimonabant 20 mg
group vs. placebo (p=0.001). A significant decrease of leptin level
from baseline was shown in the rimonabant 20 mg group compared to
placebo (p<0.001) after one year of treatment.

-- C Reactive Protein (CRP), an important inflammatory marker predictive
of cardiovascular risk, was reduced by 27% in the rimonabant 20 mg
group vs. an 11% reduction in the placebo group (p<0.01).

-- Improved insulin sensitivity as demonstrated by glycaemic and insulin
response during an Oral Glucose Tolerance Test. Over the 2 hour test,
patients metabolized glucose more efficiently with rimonabant 20 mg
compared to placebo. Blood glucose was reduced by 9% vs. baseline.

-- In this study ACOMPLIA(TM) was well tolerated in this patient
population. The most frequent side effects, mainly mild and transient,
were nausea (3.2%, 7.2% and 12.7% for placebo, rimonabant 5 mg and
rimonabant 20 mg respectively) and dizziness (6.7%, 8.4% and 10.4% for
placebo, rimonabant 5 mg and rimonabant 20 mg respectively).
Importantly the study raised no cardiovascular safety concerns for
rimonabant and no difference was observed in the three groups with
regard to depression and anxiety scores as measured by the Hospital
Anxiety and Depression (HAD) scale. Drop-out rates due to side effects
were 7% for placebo, 8.4% for rimonabant 5 mg and 15% for rimonabant
20 mg. No difference in overall drop-out rates were observed between
the three groups (37.6%, 39.9% and 36.3% for placebo, rimonabant 5 mg
and rimonabant 20 mg respectively).

"In this study Rimonabant was effective in reducing abdominal obesity, which is now known to be a major independent risk factor for cardiovascular disease," said Jean-Pierre Despres, principal investigator for RIO-Lipids and Professor in the Department of Food Sciences and Nutrition and Medicine at Laval University, and Director of Research at the Quebec Heart Institute located at the Laval Hospital Center in Quebec City, Canada. "While the weight loss seen was clinically relevant, what is truly remarkable in this study was the significant effect that rimonabant had on improving associated cardiovascular risk factors such as waist circumference, and glucose and lipid profiles."

 

[Fitness2829]

dragonfire your the man!! Thanks for the info